Press Releases AstraZeneca PLC

Equities

AZN

GB0009895292

Market Closed - London S.E. Other stock markets 11:35:29 2024-05-02 EDT			5-day change	1st Jan Change
12,156 ^GBX	-0.12%		+7.88%	+14.68%

05:18pm	AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial	MT
04:46pm	AstraZeneca: research into respiratory diseases	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K	09:04am	PU
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	07:04am	BU
Astrazeneca Joins Hands With Partners to Tackle Kenya's Cancer Burden	05-01	AQ
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio	05-01	BU
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition	04-30	AQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow	04-29	BU
Astrazeneca - Q1 2024 results	04-26	AQ
Astrazeneca: Q1 Earnings Snapshot	04-25	AQ
AlzeCure publishes its interim report for January – March 2024	04-25	AQ
Q1 2024 results	04-25	BU
Astrazeneca - Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia	04-24	AQ
Prescient Healthcare Group Appoints Two New Members to its Board of Directors	04-22	AQ
BRITAIN'S PROXY BATTLE REQUIRES A UNITED FRONT	04-18	AQ
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials	04-17	AQ
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest	04-17	AQ
Astrazeneca - New modelling reveals the escalating toll of chronic kidney disease on patients, planet and economies	04-16	AQ
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial	04-16	BU
AstraZeneca increases 2024 dividend by 7%	04-12	AQ
AstraZeneca : Special Business Approved at AGM	04-12	PU
AstraZeneca : Results of Annual General Meeting held on 11 April 2024	04-11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm